Dyne Therapeutics reports widening losses amid high-stakes trials for rare neuromuscular disease treatments without commercial revenue.
Dyne Therapeutics (NASDAQ:DYN) reported a net loss of $446.2 million for fiscal year 2025, up from $317.4 million in the prior year. The company, which lacks commercial revenue, relies on its FORCE platform to develop therapies for rare neuromuscular diseases like Duchenne muscular dystrophy and Pompe disease.
The clinical-stage firm depends on Hercules Capital for operational funding and third-party manufacturers for drug production and trials. Revenue for FY 2025 remained at $0.0, reflecting its pre-commercial status and heavy investment in R&D.
Management has prioritized advancing its pipeline, though regulatory approval and market entry remain uncertain. The company’s focus on orphan diseases contrasts with broader metabolic therapy developers like Viking Therapeutics.